Sign in
CGTX Stock Price, Chart, Stats & News
Cognition Therapeutics, Inc.
Save
82.41M
Market cap
–
Current P/E
–
Forward P/E
CGTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -48.54% |
ROE | -104.27% |
D/E | 0.02x |
Interest coverage ratio | -3676.85x |
CGTX valuation
P/E | – |
P/S | – |
P/B | 1.89x |
P/CF | -2.64x |
P/FCF | -2.18x |
P/OCF | -2.64x |
PEG | -0.10x |
EV multiple | -2.68x |
About
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist.
Similar securities
Based on sector and market capitalization
Report issue